Cargando…

The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia

Decitabine (5-aza-2′-deoxycytidine) is a hypomethylating agent used in the treatment of acute myeloid leukemia (AML). Decitabine inhibits DNA methyltransferases, causing DNA hypomethylation, and leading amongst others to re-expression of silenced tumor suppressor genes. Decitabine is indicated for t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santini, Valeria, Lübbert, Michael, Wierzbowska, Agnieszka, Ossenkoppele, Gert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989816/ https://www.ncbi.nlm.nih.gov/pubmed/34786648 http://dx.doi.org/10.1007/s12325-021-01948-8

Ejemplares similares

Clinical value of new drugs in acute myeloid leukemia
por: Ossenkoppele, Gert
Publicado: (2019)

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
por: Kwag, Daehun, et al.
Publicado: (2022)

Decitabine in the treatment of acute myeloid leukemia in elderly patients
por: Malik, Priya, et al.
Publicado: (2014)

Acute myeloid leukemia
por: Ossenkoppele, Gert
Publicado: (2018)

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
por: Shoumariyeh, Khalid, et al.
Publicado: (2021)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
por: Briski, Robert, et al.
Publicado: (2023)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Autologous Stem Cell Transplantation in elderly Acute Myeloid Leukemia
por: Ossenkoppele, Gert J, et al.
Publicado: (2013)

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
por: Becker, Heiko, et al.
Publicado: (2020)

Decitabine combined with CAG regimen in the treatment of elderly patients with acute myeloid leukemia
por: Zhao, Haitao, et al.
Publicado: (2020)

Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia
por: Zhou, Shiyong, et al.
Publicado: (2017)

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
por: Hollenbach, Paul W., et al.
Publicado: (2010)

Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia
por: Briot, Thomas, et al.
Publicado: (2017)

Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults
por: Yoo, Kwai Han, et al.
Publicado: (2020)

Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia
por: Senapati, Jayastu, et al.
Publicado: (2022)

Mechanism of Action of Decitabine in the Treatment of Acute Myeloid Leukemia by Regulating LINC00599
por: Du, Fan, et al.
Publicado: (2023)

Urinary retention after use of decitabine in acute myeloid leukemia: case report
por: Nunes, Viviane Regina Hernandez, et al.
Publicado: (2023)

Acute Myeloid Leukemia: Epidemiology and Etiology
por: Deschler, Barbara, et al.
Publicado: (2008)

Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia
por: Arthur, Christopher, et al.
Publicado: (2015)

Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment
por: de Leeuw, David C., et al.
Publicado: (2022)

Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome
por: Stomper, Julia, et al.
Publicado: (2019)

The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells
por: Shi, Mingyue, et al.
Publicado: (2019)

Teratogenic effect of decitabine in a pregnant patient with acute myeloid leukemia: a case report
por: Lee, Bee Sun, et al.
Publicado: (2022)

The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine
por: Kim, Mihee, et al.
Publicado: (2023)

Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS)
por: Klocke, Heather, et al.
Publicado: (2020)

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line
por: Aumer, Tina, et al.
Publicado: (2022)

T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report
por: Park, Sungwoo, et al.
Publicado: (2023)

P524: PHARMACODYNAMICALLY DEFINED METRONOMIC DOSING OF DECITABINE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
por: Fedorov, Kateryna, et al.
Publicado: (2023)

Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis
por: Wen, Bingbing, et al.
Publicado: (2020)

A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine
por: Yi, Jun Ho, et al.
Publicado: (2018)

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2018)

The Expression of the SLIT–ROBO Family in Adult Patients with Acute Myeloid Leukemia
por: Gołos, Aleksandra, et al.
Publicado: (2019)

Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics
por: Mayer, Jiří, et al.
Publicado: (2014)

Decitabine Downregulates TIGAR to Induce Apoptosis and Autophagy in Myeloid Leukemia Cells
por: Li, Lanzhu, et al.
Publicado: (2021)

Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia
por: Park, Hyunsung, et al.
Publicado: (2017)

Mixed-phenotype acute leukemia treated with decitabine
por: Lee, Ji-Young, et al.
Publicado: (2016)

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
por: Daver, Naval, et al.
Publicado: (2017)

Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy
por: Srivastava, Pragya, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ap1g60blpc8qcuntaq3dhf47pg